ClinicalTrials.gg
CompletedNCT05323435Updated Apr 25, 2023

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

A Phase 2 interventional study of Recombinant two-component COVID-19 vaccine (CHO cell) and COVID-19 Vaccine (Vero Cell), Inactivated in COVID-19, sponsored by Jiangsu Rec-Biotechnology Co., Ltd.. Completed at 1 site in United Arab Emirates. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Jiangsu Rec-Biotechnology Co., Ltd. · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.

Enrollment
13th of 18
300 · median 714
Started
2022
with 6 others
Phase 2
5 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
4 of 18
Jiangsu Rec-Biotechnology Co., Ltd.

Among the 18 studies testing CHO cell in COVID-19, this one is the 13th largest by enrollment, is one of 7 that started in 2022, is one of 5 in phase 2, and was the 14th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About CHO cell

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing CHO cell in COVID-19, or all of them as a file.
02

Study summary

This is a multicenter, randomized, observer-blinded, active-controlled Phase II study to evaluate the immunogenicity, safety and reactogenicity of the low dose (20μg) and high dose (40μg) of ReCOV, when administered as a booster to healthy adults aged 18 to 65 years who have completed two or three doses vaccination (prioritized two doses). Estimate 300 participants.

Read the detailed description

The study is a multicenter, randomized, observer-blinded, active-controlled trial. About 300 eligible participants will be randomized equally (1:1:1) into 20 μg ReCOV group, 40 μg ReCOV group, and the control vaccine [COVID-19 Vaccine (Vero Cell), Inactivated] group, respectively, stratified by age (18 to \< 50 years, ≥ 50 to ≤ 65 years) and the duration since the last dose of primary vaccination (90\~180 days, 181\~365 days).

All Participants will be observed for 30 minutes after study vaccination at study site if Participants will be asked to record solicited AEs within 7 days and unsolicited AEs within28 days. After 28 days post the study vaccination,all participants will have 2 on-site safety follow-up Visits on Day 90 (±15days) and on Day 180 (±15days) after the study vaccination to collect serious adverse evens (SAEs), adverse events of special interest (AESIs). During the study period, they can spontaneously report any adverse events (AEs) they experienced at any time.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years (included).
  2. Able and willing to comply with all study requirements.
  3. Willing to allow the investigators to discuss the volunteers' medical history with his/her general practitioner/personal doctors and access all medical records which are relevant to study procedures.
  4. Healthy adults, or adults with stable medical condition who have a pre-existing medical condition that does not meet any exclusion criteria. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
  5. Have completed two doses vaccination by inactivated COVID-19 vaccine prior to the study vaccination. The duration since the last primary vaccination is 90\~365 days (included) for both Phase II and Phase III stages.
  6. For females of only, willing to practice continuous effective till 90 days after the study vaccination, and have negative pregnancy tests before study vaccination.

    • Nonchildbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or (defined as amenorrhea for ≥ 12 consecutive months prior to Screening without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of investigator to confirm postmenopausal status.
    • The effective contraceptive methods include sexual abstinence or adequate contraceptive measures such as intrauterine or implanted contraceptive device, oral contraceptives, injected or implanted contraceptives, sustained-release topical contraceptives, condoms (male), diaphragm, and cervical cap, etc.
  7. Males participating in this study who are involved in heterosexual activity must agree to practice adequate contraception (as described above) and refrain from donating sperm till 90 days after receiving the study vaccination.
  8. Agreement to refrain from blood donation during the study.
  9. Provide written form (ICF) prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Laboratory confirmed SARS-CoV-2 infection, defined by the result of SARS-CoV-2 RT-PCR assay is positive.
  2. Medical history of COVID-19 disease with confirmed clinical diagnosis.
  3. Fever (oral temperature ≥ 37.5°C / axillary temperature ≥ 37.3°C) on the day of vaccination. Or having fever within recent 72 hours before the vaccination.
  4. Having abnormal results of clinical laboratory testing during screening, which is judged by the investigator with clinical significance, including the hematology, liver function, renal function, other blood chemistry, and coagulation function.
  5. History of severe allergic disease or reactions likely to be exacerbated by any component of ReCOV or COVID-19 Vaccine (Vero Cell), Inactivated, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopaenic purpura, local hypersensitive necrosis reaction (Arthus reaction), prior history of serious adverse reaction to any vaccine or drug, such as allergy, urticaria eczema, dyspnea, and angioneurotic edema.
  6. Having malignant tumor (except for skin basal cell carcinoma or carcinoma uterine cervix in situ), immune disease (e.g., [HIV] infection, systemic lupus erythematosus, rheumatoid arthritis, alienia or splenectomy, and other immune disease that may influence immune response at the investigator's discretion).
  7. Having severe and/or uncontrolled conditions, including but not limited to, acute infectious disease, cardiovascular disease, respiratory disease (including tuberculosis under anti-tuberculosis therapy), gastrointestinal disease, liver disease, renal disease, hematology disease, endocrine disorder, psychiatric condition and neurological illness (e.g., medical or family history of seizure, epilepsy, encephalopathy). Mild/moderate well-controlled comorbidities are allowed to participate.
  8. Having bleeding disorder (e.g. factor deficiency, coagulopathy or disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  9. Received or other immunomodulators, antiallergic therapy, or cytotoxicity therapy for 14 or more consecutive days within 6 months before the study vaccination. Local administration of immunosuppressant or immunomodulator is allowed (e.g., ointment, eye drops, inhalation, or nasal spray). Drugs for local administration should not be given at a dose over the recommended level in package insert or participants should have no signs of systemic exposure.
  10. Administration of immunoglobulin and/or blood product within 3 months before the study vaccination or plan to use that during the study.
  11. Continuous use of anticoagulants, such as coumarins and related anticoagulants (e.g., warfarin) or novel oral anticoagulants (e.g., apixaban, rivaroxaban, dabigatran and edoxaban).
  12. Used other drug or interventional device within 1 month before the study vaccination or plan to use that during the study, or are using other investigational drug or are within 5 half-lives after the last dose of the investigational drug.
  13. Used a subunit or inactivated vaccine within 14 days or an attenuated within 1 month (30 days) before the study vaccination, or plan to receive any other vaccines except for the seasonal influenza vaccine, or other vaccines for emergency use (e.g., to prevent tetanus and rabies) during the study.
  14. Prior receipt of any investigational or licensed COVID-19 vaccine except for the primary vaccination with inactivated vaccines according to the protocol, or plan to receive any COVID-19 vaccine except for the investigational products during the study stage.
  15. Suspected or known current alcohol or drug dependency.
  16. Having for intramuscular injection or intravenous blood sampling.
  17. Pregnancy, lactation or plan to become pregnant within 90 days after receiving study vaccine.
  18. Staff of study site, sponsor, and contract research organization (CRO) taking part in study conduct.
  19. At investigator's discretion, any other significant disease, disorder or finding that may increase the risk because of participation in the study, or prevent from participation in the study, or impair interpretation of the study data.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Recombinant Two-Component COVID-19 Vaccine (CHO cell), 20μg

    Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 20μg)

    Biological: Recombinant two-component COVID-19 vaccine (CHO cell)

  • Experimental
    Recombinant Two-Component COVID-19 Vaccine (CHO cell), 40μg

    Antigen: NTD-RBD-foldon protein, sodium dihydrogen phosphate, disodium hydrogen phosphate, sucrose, glycine, polysorbate 80 Adjuvant (BFA03): squalene, alpha-tocopherol, polysorbate 80, sodium chloride, potassium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate (ReCOV for short, 40μg)

    Biological: Recombinant two-component COVID-19 vaccine (CHO cell)

  • Active comparator
    COVID-19 Vaccine (Vero Cell), Inactivated

    Antigen: inactivated SARS-CoV-2 Virus (19nCoV-CDC-Tan-HB02 strain) Adjuvant: aluminum hydroxide Excipients: disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride

    Biological: COVID-19 Vaccine (Vero Cell), Inactivated

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity at Phase II Study

    The GMT of live-virus neutralizing antibody against SARS-CoV-2 prototype at 14 days after the booster vaccination.

    Time frame: at 14 days after the booster vaccination

  2. Immunogenicity at Phase II Study

    The SCR of live-virus neutralizing antibody against SARS-CoV-2 prototype at 14 days after the booster vaccination

    Time frame: at14 days after the booster vaccination

  3. Safety at Phase II Study

    The occurrence of solicited local and systemic adverse events (AEs) within 7 days after the booster vaccination

    Time frame: within 7 days after the booster vaccination

  4. Safety at Phase II Study

    The occurrence of unsolicited AEs within 28 days after the booster vaccination

    Time frame: within 28 days after the booster vaccination

  5. Safety at Phase II Study

    The occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs) till 6 months after the booster vaccination

    Time frame: till 6 months after the booster vaccination

07

Study locations

1 site
  • AI Kuwait Hospital
    Dubai, 7272, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make individual participant data (IPD) available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2022, 1 month.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 1 month is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Apr 12, 2022
StartActual
May 30, 2022
Primary completionActual
Jul 5, 2022
CompletionActual
Jan 16, 2023
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323435
Lead sponsor
Jiangsu Rec-Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
May 30, 2022
Primary completion
Jul 5, 2022
Completion
Jan 16, 2023
Last update
Apr 25, 2023

Study contacts

Suad Al Hannawi, Dr.
principal investigator · AI Kuwait Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion